5-hydroxymethylcytosine: a potential therapeutic target in cancer

Epigenomics. 2014;6(5):503-14. doi: 10.2217/epi.14.39.

Abstract

The ten-eleven translocation enzymes catalyze the conversion of 5-methylcytosine to 5-hydroxymethylcytosine, a distinct epigenetic mark that has an integral role in active demethylation. Genes that regulate the distribution and amount of 5-hydroxymethylcytosine in the genome could be suitable therapeutic targets to correct abnormal methylation in cancer. Here, we present an overview of the role of the 5-hydroxymethylcytosine pathway in human disease and discuss the emergence of innovative techniques that can map the distribution of 5-hydroxymethylcytosine at high resolution. In the context of current epigenetic therapies and by using recent functional studies, we propose plausible mechanisms to target the 5-hydroxymethylcytosine pathway in cancer. As the study of 5-hydroxymethylcytosine is still in its infancy, we provide future perspectives.

Keywords: 5-hydroxymethylcytosine; 5-methylcytosine; cancer; demethylation; epigenetic therapy; hydroxymethylation; methylation.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • 5-Methylcytosine / metabolism
  • Animals
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Cytosine / analogs & derivatives*
  • Cytosine / metabolism
  • DNA (Cytosine-5-)-Methyltransferases / metabolism
  • DNA Methylation*
  • Epigenesis, Genetic* / drug effects
  • Humans
  • Neoplasms / drug therapy
  • Neoplasms / genetics*
  • Neoplasms / metabolism*

Substances

  • Antineoplastic Agents
  • 5-hydroxymethylcytosine
  • 5-Methylcytosine
  • Cytosine
  • DNA (Cytosine-5-)-Methyltransferases